Long at the forefront of gene-sequencing and -therapy technology, Illumina is picking up steam thanks to the proliferation of DNA sequencing across a variety of medical applications—including tracking infectious diseases like COVID-19. Illumina says there are now some 70 countries using its tech to monitor and analyze samples of the coronavirus, hoping to track how it could mutate into variants. Just as Illumina has helped sharply reduce the cost of genetic sequencing, it aims to do the same for cancer diagnostics via its acquisition of biotech Grail (though the deal faces scrutiny from antitrust regulators).
CTW-2021-20-Illumina
Courtesy of Illumina

Company Information

As of 5/23/2022
Country
U.S.
Headquarters
San Diego
Industry
Scientific, Photographic and Control Equipment
CEO
Francis A. deSouza
Company Type
Public
Ticker
ILMN
Revenues ($M)
$4,526
Profits ($M)
$762
Market Value ($M)
$54,855.8
Employees
10,775
Market value as of March 31, 2022.

Change the World

Impact Segment
Public Health/Nutrition
Sector
Technology
Prior Year Rank
-

Historical Data

YearRevenues ($M)Profits ($M)
2019$3,333$826
FortuneDataStore ad
Lists ranking Illumina
RANK651
Fortune 500 - 2022This year’s Fortune 500 marks the 68th running of ...READ MORE